Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
21 Octubre 2021 - 8:15AM
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX:
IDXG), a fully integrated commercial company that provides
clinically relevant molecular diagnostic tests and pathology
services for improved patient diagnosis and management, today
announced that on September 14th 2021, the United States Patent and
Trademark Office granted it a Patent (U.S. PTO Number 11,118,231
B2) for use of microRNAs for distinguishing benign from malignant
thyroid neoplasms. This patent covers the underlying technology of
its ThyraMIR® microRNA Classifier.
MicroRNAs are small, non-coding RNAs that bind
to messenger RNA and regulate expression of proteins involved in
human cancers, including thyroid cancer.
ThyraMIR®, our micro-RNA classifier, is designed
to work in concert with Interpace’s NGS based ThyGeNEXT® test to
risk stratify indeterminate Thyroid nodules. By measuring the
expression levels of 10 microRNAs, ThyraMIR®, in combination with
ThyGeNEXT® provide actionable rule-in and rule-out results,
reducing unnecessary Thyroidectomy surgeries and improving patient
care.
Alidad Mireskandari, Ph.D., MBA, Chief
Development Officer of Interpace Biosciences stated, “We are
pleased to announce the approval of this patent by the US PTO. This
patent adds to our existing portfolio of Intellectual Property that
protects our innovative products and unique technology around the
use of micro RNAs as key diagnostic analytes.”
About Interpace Biosciences
Interpace Biosciences is an emerging leader in
enabling personalized medicine, offering specialized services along
the therapeutic value chain from early diagnosis and prognostic
planning to targeted therapeutic applications.
Clinical services, through Interpace
Diagnostics, provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has five
commercialized molecular tests and one test in a clinical
evaluation program (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; PanDNA, a
“molecular only” version of PancraGEN® that provides physicians a
snapshot of a limited number of factors; ThyGeNEXT® for the
diagnosis of thyroid cancer from thyroid nodules utilizing a next
generation sequencing assay; ThyraMIR® for the diagnosis of thyroid
cancer from thyroid nodules utilizing a proprietary gene expression
assay; and RespriDX® that differentiates lung cancer of primary
versus metastatic origin. In addition, BarreGEN®, a molecular based
assay that helps resolve the risk of progression of Barrett’s
Esophagus to esophageal cancer, is currently in a clinical
evaluation program (CEP) whereby we gather information from
physicians using BarreGEN® to assist us in gathering clinical
evidence relative to the safety and performance of the test and
also providing data that will potentially support payer
reimbursement.
Pharma services, through Interpace Pharma
Solutions, provides pharmacogenomics testing, genotyping,
biorepository and other customized services to the pharmaceutical
and biotech industries. Pharma services also advances personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goals
of delivering safer, more effective drugs to market more quickly,
while also improving patient care.
For more information, please visit Interpace
Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company’s future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company’s control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company’s actual results to be materially different from those
expressed or implied by any forward-looking statements including,
but not limited to, the adverse impact of the COVID-19 pandemic on
the Company’s operations and revenues, the substantial doubt about
the Company’s ability to continue as a going concern, the
possibility that the Company’s estimates of future revenue, cash
flows and adjusted EBITDA may prove to be materially inaccurate,
the Company’s history of operating losses, the Company’s ability to
adequately finance its business, the Company’s ability to repay
borrowings under its new credit facility as well as its $7.5M
bridge loans from its private equity investors, the Company’s
dependence on sales and reimbursements from its clinical services,
the Company’s ability to retain or secure reimbursement including
its reliance on third parties to process and transmit claims to
payers and the adverse impact of any delay, data loss, or other
disruption in processing or transmitting such claims, the Company’s
revenue recognition being based in part on estimates for future
collections which estimates may prove to be incorrect, and the
Company’s ability to remediate material weaknesses in internal
controls. Additionally, all forward-looking statements are subject
to the “Risk Factors” detailed from time to time in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2020 filed with the Securities and Exchange Commission, Current
Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of
these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
Contacts:
Investor RelationsInterpace Biosciences,
Inc.(855)-776-6419Info@Interpace.com
Interpace Biosciences (NASDAQ:IDXG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Interpace Biosciences (NASDAQ:IDXG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024